U.S. TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

The U.S. transthyretin amyloidosis treatment market is estimated to be valued at USD 71.8 Mn in 2026 and is expected to reach USD 138.2 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.

Increasing research and development efforts aimed at innovative treatments, alongside heightened collaborations between pharmaceutical companies and research institutions for clinical trials, are crucial in boosting demand for transthyretin amyloidosis treatment. Additionally, awareness initiatives led by non-profit organizations and support groups are expected to propel market growth. However, challenges such as the scarcity of approved drugs and high costs associated with treatment may hinder this growth trajectory in the coming years.

Insights By Type - Genetic factors drive demand for wild type amyloidosis (wATTR-CM)

In terms of type, wild type amyloidosis (wATTR-CM) segment is estimated to contribute the highest market share of 68.7% in 2026 due to increased awareness and diagnosis. There has been a significant increase in awareness regarding transthyretin amyloidosis, leading to improved diagnostic rates. Enhanced understanding among healthcare professionals and the public about the symptoms and risks associated with wATTR-CM facilitates earlier diagnosis and treatment initiation.

Insights By Drug Type - Novel drug approvals drive Tafamidis segment growth

In terms of drug type, tafamidis segment is estimated to contribute the highest market share of 40.8% in 2026 being the first FDA-approved treatment for hATTR amyloidosis. Its oral administration enhances patient compliance, while clinical evidence shows it stabilizes neurological function and reduces mortality. Patent protection until 2030 further secures its market position and encourages rapid adoption among healthcare providers.

Insights By Distribution Channel – Hospital’s expertise drives distribution through hospital pharmacies

In terms of distribution channel, hospital pharmacies segment is expected to contribute the highest market share of 49.7% in 2026 attributed to hospital’s expertise in managing complex cases of transthyretin amyloidosis. These specialized centers provide comprehensive care through interdisciplinary teams, facilitating integrated diagnostics and treatment options. The need for in-patient care during disease exacerbations further consolidates procurement through hospital pharmacies, enhancing their market position.

Top Strategies Followed by the U.S. Transthyretin Amyloidosis Treatment Market Players

• Established players in the U.S. transthyretin amyloidosis treatment industry focus extensively on R&D to innovate new drugs and therapies. For example, companies like Pfizer, Inc. invest over US$ 8 billion annually in R&D activities to develop novel treatment options for rare diseases like transthyretin amyloidosis.
• Mid-level companies compete by offering more cost-effective generic versions of patented drugs. For instance, several firms launch affordable biosimilars once major brand names lose intellectual property protection. They also form useful alliances with contract manufacturing organizations and medical device makers to expand production capabilities at a lower outlay.
• Small-scale players in the market focus on niche areas and hard-to-treat patient subgroups. Some target specific gene mutations or stages of the disease through specialized medication and services. To remain competitive, such companies leverage new-age technologies like 3D printing for individualized medicine and telehealth for remote monitoring.

Emerging Startups in the U.S. Transthyretin Amyloidosis Treatment Market

• Several startups are developing innovative solutions using cutting-edge technologies. Others like Anthropic are engaged in developing smart biosensors integrated with mobile health apps for at-home monitoring of disease progression and treatment response. Such technologies have potential to transform diagnostics and therapeutics landscape.
• Sustainability is a key focus area for many startups. Firms like BioCellection are working on sustainable alternatives to traditional plastics using agricultural waste for single-use medical products. Green chemistry approaches could help address concerns around material disposal.
• Many startups identify gaps in serving niche patient groups and address their needs. Some focus on orphan indications through specialized orphan drug development programs. Others form strategic partnerships with research organizations to advance customized therapies.

• On October 9, 2024, Alnylam Pharmaceuticals, Inc., the RNAi therapeutics company, announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for vutrisiran, an investigational RNAi therapeutic aimed at treating ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran, the generic name for AMVUTTRA, is already FDA-approved for treating the polyneuropathy of hereditary ATTR amyloidosis in adults.
• On February 5, 2024, BridgeBio Pharma, Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for acoramidis, an investigational treatment for ATTR amyloidosis with cardiomyopathy (ATTR-CM). This application is based on positive results from the ATTRibute-CM trial.
• In March 2023, AstraZeneca, a global biopharmaceutical company, announced the results of the NEURO-TTRansform Phase III trial involving patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The trial demonstrated that eplontersen successfully met its co-primary endpoints over a period of 66 weeks.

Market Driver - Increasing product approvals/launches

With the rising prevalence of transthyretin amyloidosis, pharmaceutical companies are intensifying efforts to develop novel treatments. In December 2023, Ionis Pharmaceuticals, Inc., a pharmaceutical company, and AstraZeneca, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Ionis and AstraZeneca's WAINUA (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.

Market Challenge - Lack of awareness in early stages

One of the key challenges in the U.S. transthyretin amyloidosis treatment industry is the lack of awareness about the disease in its early stages. Transthyretin amyloidosis is often misdiagnosed in its early stages due to vague symptoms, leading to delayed treatment and irreversible damage. Raising awareness among healthcare providers and the public about early signs is essential for timely intervention. Implementing educational initiatives and screening programs can significantly improve early detection and health outcomes for at-risk populations.

Market Opportunity - Growing funding for research

Growing funding for research presents a key opportunity in the U.S. transthyretin amyloidosis treatment industry. Increased financial support from government and private organizations aims to enhance understanding of the disease's pathogenesis and develop advanced diagnostics and therapies. This investment has already led to the U.S. Food and Drug Administration approvals for multiple disease-modifying drugs, with promising candidates in the pipeline expected to improve treatment efficacy and patient outcomes.

Key Takeaways from Analyst

The increasing prevalence rate of the disease is expected to be a major growth driver as it raises awareness and demand for effective treatment options. In addition, recent drug approvals for hereditary and wild-type ATTR amyloidosis provide patients with important new therapies.

In addition, recent drug approvals for hereditary and wild-type ATTR amyloidosis provide patients with important new therapies. This has expanded treatment choices for physicians and broadened the addressable patient pool.

High drug prices remain a restraint for market expansion as not all patients have adequate insurance coverage for the costly medications. This could limit their adoption. Nonetheless, pharmaceutical companies are making efforts to offer patient support programs to improve access.

• By Type Insights (Revenue, USD Mn, 2021 - 2033)
• • Hereditary Transthyretin Amyloidosis (hATTR-CM)
  • Wild Type Amyloidosis (wATTR-CM)
• By Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
• • Tafamidis
  • Diflunisal
  • Inotersen
  • Patisiran
  • Tolcapone
  • Others
• By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Key Players Insights
• • Alnylam Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Prothena Corporation Plc
  • GSK plc
  • Ionis Pharmaceuticals, Inc.
  • SOM Innovation Biotech, S.L.
  • Eidos Therapeutics
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Acrotech Biopharma
  • Attralus, Inc.